Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Oct 16, 2019 (7 years ago)

Isotretinoin Capsules

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Impurities/Degradation Specifications: Tretinoin levels slightly above specification limits.

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Isotretinoin Capsules, USP 10 mg. Rx Only, 3 Prescription Blister Packs of 10- Capsules Each (30 Capsules)-. Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807. NDC 69238-1174-3

Affected NDC 69238-1174-03

Compare with the code on your package — it is the most precise check available.

Drug: Isotretinoin

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Isotretinoin
NDC 69238-1174
10 mg/1 Capsule, Liquid Filled
Oral
Amneal Pharmaceuticals LLC Rx
Recalling firm
Amneal Pharmaceuticals, Inc.
NDC code
69238-1174-3
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0321-2020 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Isotretinoin recalls

See all
Class II · Moderate risk

Isotretinoin Capsules

Superpotent Drug: The 3-month stability result for assay was found to be above specification limit

Ongoing Wrong potency / content Teva Pharmaceuticals USA, Inc NDC 0591-2436-45 D-0439-2024

Other recalls by Amneal Pharmaceuticals, Inc.

All 2019 recalls
Class III · Low risk

Primidone Tablets

Cross Contamination with Other Products: due to a potential for cross-contamination with Acemetacin API due to an issue at the API manufacturer.

Ongoing Cross-contamination Amneal Pharmaceuticals, LLC D-0585-2026
Class II · Moderate risk

traMADol Hydrochloride Tablets

Failed Impurities/Degradation Specifications: N-nitroso-desmethyl-tramadol impurity (NDSRI) was found out of the specification at 24-month stability interval during Long term stability (25¿C/60%RH).

Ongoing Nitrosamine impurity Amneal Pharmaceuticals, LLC NDC 60219-2348-5 D-0408-2026
Class I · High risk

Magnesium Sulfate in Water for Injection

Product mix up: a foil pouch labeled "Magnesium Sulfate in Water for Injection, 4 g/100 mL" actually contained an IV bag of Tranexamic Acid instead.

Ongoing Labeling / mix-up Amneal Pharmaceuticals, LLC NDC 70121-1720-3 D-0478-2026
Class II · Moderate risk

chlorproMAZINE Hydrochloride Tablets

Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging was detected with presence of a micro-organism. No micro-organism was detected on any tablets.

Ongoing Particulate / foreign matter Amneal Pharmaceuticals, LLC NDC 69238-1062-1 D-0619-2025